Metastasis of ovarian cancer is regulated by microRNAs. This study focused on the effects of miR-30a-5p on ovarian cancer migration and invasion. Our results showed that the miR-30a-5p and mucin type O-glycan biosynthesis are closely related to ovarian cancer, and that miR-30a-5p was downregulated in ovarian cancer cells. miR-30a-5p overexpression reduced cell viability and inhibited migration and invasion in HO-8910 and HO-8910PM cells. S phase kinase-associated protein 2 (SKP2), B cell lymphoma 9 (BCL9), and NOTHC1 are direct target genes of miR-30a-5p. MTDH, SKP2, BCL9, and NOTCH1 genes were overexpressed in ovarian cancer cells, and they are direct target genes of miR-30a-5p. miR-30a-5p overexpression inhibited epithelial–mesenchymal transition (EMT) process, while upregulation of SKP2, BCL9, and NOTCH1 gene expression levels reduced the inhibition of EMT process by miR-30a-5p. miR-30a-5p was lowly expressed in ovarian cancer, and such a phenomenon is related to ovarian cancer metastasis. miR-30a-5p might inhibit the migration and invasion of ovarian cancer cells by downregulating the expression of SKP2, BCL9, and NOTCH1 genes.
Bou ZgheibN., XiongY., MarchionD.C., BicakuE., ChonH.S., SticklesX.B., et al. (2012). The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol, 41, 179–188.
3.
ChenJ.S., LiH.S., HuangJ.Q., DongS.H., HuangZ.J., YiW., et al. (2016). MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. Cancer Lett, 375, 73–83.
4.
ChungY.H., LiS.C., KaoY.H., LuoH.L., ChengY.T., LinP.R., et al. (2017). miR-30a-5p inhibits epithelial-to-mesenchymal transition and upregulates expression of tight junction protein claudin-5 in human upper tract urothelial carcinoma cells. Int J Mol Sci, 18, E1826.
5.
CullenB.R. (2004). Transcription and processing of human microRNA precursors. Mol Cell, 16, 861–865.
6.
DengS., CalinG.A., CroceC.M., CoukosG., and ZhangL. (2008). Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 7, 2643–2646.
7.
DingL., LiR., HanX., ZhouY., ZhangH., CuiY., et al. (2017). Inhibition of Skp2 suppresses the proliferation and invasion of osteosarcoma cells. Oncol Rep, 38, 933–940.
8.
FernandezS., RisolinoM., MandiaN., TalottaF., SoiniY., IncoronatoM., et al. (2015). miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene, 34, 3240–3250.
9.
GabraH. (2014). Introduction to managing patients with recurrent ovarian cancer. EJC Suppl, 12, 2–6.
10.
GonzalezD.M., and MediciD. (2014). Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal, 7, re8.
11.
GrassiM.L., PalmaC.S., ThomeC.H., LanfrediG.P., PoerschA., and FacaV.M. (2017). Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control. J Proteomics, 151, 2–11.
12.
GuptaN., XuZ., El-SehemyA., SteedH., and FuY. (2013). Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecol Oncol, 130, 200–206.
13.
HanX., ZhenS., YeZ., LuJ., WangL., LiP., et al. (2017). A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells. Cell Physiol Biochem, 41, 973–986.
14.
HuangR.Y., ChungV.Y., and ThieryJ.P. (2012). Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets, 13, 1649–1653.
15.
IorioM.V., VisoneR., Di LevaG., DonatiV., PetroccaF., CasaliniP., et al. (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699–8707.
16.
JiaW., EnehJ.O., RatnaparkheS., AltmanM.K., and MurphM.M. (2011). MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9. Mol Cancer Res, 9, 1732–1745.
17.
KalluriR., and WeinbergR.A. (2009). The basics of epithelial-mesenchymal transition. J Clin Invest, 119, 1420–1428.
18.
KobayashiM., SalomonC., TapiaJ., IllanesS.E., MitchellM.D., and RiceG.E. (2014). Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med, 12, 4.
19.
KudelkaM.R., JuT., Heimburg-MolinaroJ., and CummingsR.D. (2015). Simple sugars to complex disease—mucin-type O-glycans in cancer. Adv Cancer Res, 126, 53–135.
20.
LedermannJ., HarterP., GourleyC., FriedlanderM., VergoteI., RustinG., et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med, 366, 1382–1392.
21.
LeeS.H., HatakeyamaS., YuS.Y., BaoX., OhyamaC., KhooK.H., et al. (2009). Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of alpha2beta1 integrin complex. J Biol Chem, 284, 17157–17169.
22.
LiL., KangL., ZhaoW., FengY., LiuW., WangT., et al. (2017). miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. Cancer Lett, 400, 89–98.
23.
LiW., LiuC., ZhaoC., ZhaiL., and LvS. (2016a). Downregulation of beta3 integrin by miR-30a-5p modulates cell adhesion and invasion by interrupting Erk/Ets1 network in triple-negative breast cancer. Int J Oncol, 48, 1155–1164.
24.
LiY., ZhangT., ZhouY., SunY., CaoY., ChangX., et al. (2016b). A Presenilin/Notch1 pathway regulated by miR-375, miR-30a, and miR-34a mediates glucotoxicity induced-pancreatic beta cell apoptosis. Sci Rep, 6, 36136.
25.
LingX.H., ChenZ.Y., LuoH.W., LiuZ.Z., LiangY.K., ChenG.X., et al. (2016). BCL9, a coactivator for Wnt/beta-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncol Lett, 11, 2001–2008.
26.
LuJ., GetzG., MiskaE.A., Alvarez-SaavedraE., LambJ., PeckD., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834–838.
27.
ManiM., CarrascoD.E., ZhangY., TakadaK., GattM.E., Dutta-SimmonsJ., et al. (2009). BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res, 69, 7577–7586.
28.
MaupinK.A., SinhaA., EugsterE., MillerJ., RossJ., PaulinoV., et al. (2010). Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS One, 5, e13002.
29.
NilsenT.W. (2007). Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet, 23, 243–249.
30.
ParaskevopoulouM.D., GeorgakilasG., KostoulasN., VlachosI.S., VergoulisT., ReczkoM., et al. (2013). DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res, 41, W169–W173.
31.
QiF., HeT., JiaL., SongN., GuoL., MaX., et al. (2015). The miR-30 family inhibits pulmonary vascular hyperpermeability in the premetastatic phase by direct targeting of Skp2. Clin Cancer Res, 21, 3071–3080.
32.
SanchezN., GallagherM., LaoN., GallagherC., ClarkeC., DoolanP., et al. (2013). miR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3. PLoS One, 8, e65671.
33.
SunX., CuiM., ZhangA., TongL., WangK., LiK., et al. (2016). miR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist. J Exp Clin Cancer Res, 35, 10.
34.
TanH., HeQ., GongG., WangY., LiJ., WangJ., et al. (2016). miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. Int J Oncol, 48, 181–190.
35.
ThomsonD.W., BrackenC.P., and GoodallG.J. (2011). Experimental strategies for microRNA target identification. Nucleic Acids Res, 39, 6845–6853.
36.
Tovar-CamargoO.A., TodenS., and GoelA. (2016). Exosomal microRNA biomarkers: emerging frontiers in colorectal and other human cancers. Expert Rev Mol Diagn, 16, 553–567.
37.
VlachosI.S., and HatzigeorgiouA.G. (2013). Online resources for miRNA analysis. Clin Biochem, 46, 879–900.
38.
VlachosI.S., ZagganasK., ParaskevopoulouM.D., GeorgakilasG., KaragkouniD., VergoulisT., et al. (2015). DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res, 43, W460–W466.
39.
WangL., YeX., CaiX., SuJ., MaR., YinX., et al. (2015). Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells. Oncotarget, 6, 18027–18037.
40.
WangY., QiuC., LuN., LiuZ., JinC., SunC., et al. (2018). FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner. Int J Oncol, 52, 2130–2142.
41.
WeiW., YangY., CaiJ., CuiK., LiR., WangH., et al. (2016). miR-30a-5p suppresses tumor metastasis of human colorectal cancer by targeting ITGB3. Cell Physiol Biochem, 39, 1165.
42.
WeingartenC., JenudiY., TshuvaR.Y., MoskovichD., AlfandariA., HercbergsA., et al. (2018). The interplay between epithelial-mesenchymal transition (EMT) and the thyroid hormones-alphavbeta3 axis in ovarian cancer. Horm Cancer, 9, 22–32.
43.
XiaB., YangS., LiuT., and LouG. (2015). miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer, 14, 57.
44.
XiangY., MaN., WangD., ZhangY., ZhouJ., WuG., et al. (2014). miR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene, 33, 378–386.
45.
YamadaS., YanamotoS., NaruseT., MatsushitaY., TakahashiH., UmedaM., et al. (2016). Skp2 regulates the expression of MMP-2 and MMP-9, and enhances the invasion potential of oral squamous cell carcinoma. Pathol Oncol Res, 22, 625–632.
46.
YeJ., PanQ., ShangY., WeiX., PengZ., ChenW., et al. (2015). Core 2 mucin-type O-glycan inhibits EPEC or EHEC O157:H7 invasion into HT-29 epithelial cells. Gut Pathog, 7, 31.
47.
YoshidaC.A., KawaneT., MoriishiT., PurushothamanA., MiyazakiT., KomoriH., et al. (2014). Overexpression of Galnt3 in chondrocytes resulted in dwarfism due to the increase of mucin-type O-glycans and reduction of glycosaminoglycans. J Biol Chem, 289, 26584–26596.
48.
YuP.N., YanM.D., LaiH.C., HuangR.L., ChouY.C., LinW.C., et al. (2014). Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer, 134, 542–551.
49.
ZhaoJ.J., LinJ., ZhuD., WangX., BrooksD., ChenM., et al. (2014). miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Res, 74, 1801–1813.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
